SCHEMBL1428673

SCHEMBL1428673

O=C1C(=Cc2c(-c3ccccc3)[nH]c3ccccc23)Sc2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.46
MEN1 O00255 8/20 0.46
KMT2A Q03164 8/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
RAB9A P51151 2/20 0.46
MAPK1 P28482 2/20 0.46
CASP3 P42574 1/20 0.46
SENP8 Q96LD8 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
SENP6 Q9GZR1 1/20 0.46
PIK3CA P42336 1/20 0.44
MTOR P42345 1/20 0.44
PIK3CG P48736 1/20 0.44
POLB P06746 2/20 0.44
NPC1 O15118 2/20 0.44
HCRTR1 O43613 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4325723 1.00 MAPT (0.46) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4314981 0.90 PIK3CA (0.48) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1428867 0.90 PIK3CA (0.48) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1429523 0.86 PTGS2 (0.42) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4325923 0.86 PTGS2 (0.42) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1428478 0.86 PIK3CA (0.44) MEN1KMT2ASMN1; SMN2MAPK1PIK3CA
SCHEMBL4337432 0.86 PIK3CA (0.50) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL1428397 0.86 PIK3CA (0.50) MAPTMEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL4320531 0.86 PIK3CA (0.44) MEN1KMT2ASMN1; SMN2MAPK1PIK3CA
SCHEMBL4317406 0.83 MAPT (0.51) MAPTMEN1KMT2ASMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2300460-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2011-03-30 EP claimed
WO-2009155042-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-23 WO claimed
US-20090311217-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-17 US claimed
EP-2300460-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES Wyeth LLC (US) 2011-03-30 EP disclosed
WO-2009155042-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-23 WO disclosed
US-20090311217-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES WYETH (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090311217-A1 3-SUBSTITUTED-1H-INDOLE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES MTOR, RICTOR, PDPK1 MAPT 1103/4885MEN1 827/4885KMT2A 1721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.